U.S. FDA Accepts for Priority Review Supplemental Biologics

Applications based on results from Phase 3 COMMANDS study in which first-in-class Reblozyl demonstrated a highly statistically significant and clinically meaningful improvement compared to an erythropoiesis-stimulating agent in patients with very low/low/intermediate-risk MDSU.S. FDA has assigned a target action dat...

Related Keywords

, Bristol Myers Squibb , Origar Beta , Noah Berkowitz , Maedica Bucur , European Medicines Agency , Twitter , Facebook , Hematology Development , Youtube , Exchange Commission , Instagram , Drug Administration , Linkedin , Acceleron Pharma Inc , Myelodysplastic Syndromes Foundation , Biologics License Application , Priority Review , Prescription Drug User Fee Act , Bristol Myers , Acceleron Pharma , Prescribing Information , Product Characteristics , Myers Squibb , Better Future , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , Accessed March ,